Astrazeneca (AZN) Stock
Global pharmaceutical giant developing prescription medicines for patients. Here's the price, business snapshot, and what's worth knowing about Astrazeneca in October 2026.
AstraZeneca PLC (AZN) is a large‑cap global biopharmaceutical company focused on discovery, development and commercialisation of prescription medicines, with particular strength in oncology, cardiovascular, renal & metabolic (CVRM), and respiratory therapies. The firm combines a broad marketed portfolio with an active R&D pipeline and significant investment in biologics and precision medicines. For investors, key considerations include steady revenue from established drugs, growth driven by newer oncology and rare‑disease launches, and continued R&D spend that can both support long‑term value and create near‑term earnings variability. The company operates globally, exposing it to different regulatory and pricing environments and currency movements. AstraZeneca has historically paid dividends, but dividend levels and share price can fluctuate with trial outcomes, patent expiries and competition. This summary is educational only — not personalised investment advice — and investors should weigh growth potential against clinical, regulatory and commercial risks.
Why It’s Moving
AstraZeneca Pipeline Momentum Builds Ahead of Q3 Earnings as Oncology and Rare Disease Wins Offset Trial Setbacks
- Regulatory wins bolster portfolio: The FDA granted accelerated approval to Ultomiris for IgA nephropathy, marking its fifth US indication, while ZEGFROVY became available for specific lung cancer mutations, expanding AZN's addressable market.
- Clinical trial successes drive optimism: Phase III results showed TAGRISSO plus savolitinib reduced disease progression risk by 45% in lung cancer, and IMFINZI combinations cut recurrence risk by 49% in bladder cancer, reinforcing the company's oncology leadership.
- Strategic partnerships and pipeline outlook: A new AI collaboration with Oracle aims to refine clinical research efficiency, while analysts highlight that robust pipeline strength targets $80bn in revenues by 2030, potentially offsetting near-term headwinds from eplontersen study failures.
AstraZeneca Pipeline Momentum Builds Ahead of Q3 Earnings as Oncology and Rare Disease Wins Offset Trial Setbacks
- Regulatory wins bolster portfolio: The FDA granted accelerated approval to Ultomiris for IgA nephropathy, marking its fifth US indication, while ZEGFROVY became available for specific lung cancer mutations, expanding AZN's addressable market.
- Clinical trial successes drive optimism: Phase III results showed TAGRISSO plus savolitinib reduced disease progression risk by 45% in lung cancer, and IMFINZI combinations cut recurrence risk by 49% in bladder cancer, reinforcing the company's oncology leadership.
- Strategic partnerships and pipeline outlook: A new AI collaboration with Oracle aims to refine clinical research efficiency, while analysts highlight that robust pipeline strength targets $80bn in revenues by 2030, potentially offsetting near-term headwinds from eplontersen study failures.
When is the next earnings date for ASTRAZENECA PLC (AZN)?
The next earnings date for AstraZeneca has not been confirmed yet. Based on the company's historical reporting pattern of approximately three-month intervals, the upcoming release is expected in late January 2027. This report will cover the fourth quarter and full-year results for fiscal year 2026.
Why You’ll Want to Watch This Stock
Pipeline drives growth
AstraZeneca’s R&D pipeline, especially in oncology and precision medicines, can support future revenue, though trial outcomes and approvals are uncertain.
Global footprint matters
Wide geographic reach diversifies revenue but brings exposure to regulatory, pricing and currency risks that can affect results.
Innovation and spending
Heavy investment in biologics and new modalities underpins long‑term potential while creating earnings variability in the near term.
